Resolves Yes if Resolves Yes if the olpasiran phase 3 trial meets its primary endpoint, as reported by the sponsor in a press release or peer-reviewed publication by the close date.
Outcome verified from clinicaltrials.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
Amgen announced on May 30, 2026, that the Phase 3 OCEAN(a)-Outcomes trial of olpasiran met its primary composite MACE endpoint with a statistically significant result, well before the market's January 31, 2027 close date. The outcome is already determined and publicly reported.
